2C-B (4-Bromo-2,5-dimethoxyphenethylamine)
Synthetic phenethylamine psychedelic created by Alexander Shulgin. 5-HT2A/2C agonist with effects lasting 4-6 hours. Often described as a gentler psychedelic with more manageable headspace than tryptamines. Metabolized by MAO-A and MAO-B. Shorter duration and half-life than classical psychedelics. Popular at low doses (5-15 mg) for empathogenic effects.
Projected serum levels — 20 mg, as needed (shown daily)
Maintenance schedule: 20 mg as needed (shown daily) (oral).
Modeled steady state after ~1 days: peak ≈ 5.5 mg, trough ≈ 0.001 mg body load. Population-based estimate over 15 days for a 20 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Psychedelic
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 2.5 h
- Common dose
- 20 mg
- Reference dose range
- 10–40 mg (single dose)
- Suggested cadence
- as needed (shown daily)
Documented interactions
-
danger
1P-LSD (1-Propionyl-LSD) + 2C-B (4-Bromo-2,5-dimethoxyphenethylamine)
1P-LSD (1-Propionyl-LSD) and 2C-B (4-Bromo-2,5-dimethoxyphenethylamine) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…
-
danger
25I-NBOMe + 2C-B (4-Bromo-2,5-dimethoxyphenethylamine)
25I-NBOMe and 2C-B (4-Bromo-2,5-dimethoxyphenethylamine) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
-
danger
2C-I (2,5-Dimethoxy-4-iodophenethylamine) + 2C-B (4-Bromo-2,5-dimethoxyphenethylamine)
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) reversible_inhibitor of MAO-A predicted to change 2C-I (2,5-Dimethoxy-4-iodophenethylamine) AUC by ~2.00x
-
danger
3-MeO-PCP (3-Methoxyphencyclidine) + 2C-B (4-Bromo-2,5-dimethoxyphenethylamine)
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and 3-MeO-PCP (3-Methoxyphencyclidine) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered…
-
danger
4-AcO-DMT (Psilacetin) + 2C-B (4-Bromo-2,5-dimethoxyphenethylamine)
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and 4-AcO-DMT (Psilacetin) both push the serotonin 5HT1A, serotonin 5HT2A, and serotonin 5HT2C in the same direction.
-
danger
5-HTP (5-Hydroxytryptophan) + 2C-B (4-Bromo-2,5-dimethoxyphenethylamine)
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and 5-HTP (5-Hydroxytryptophan) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…
Serum checks 178 modeled interaction pairings for 2c-b (4-bromo-2,5-dimethoxyphenethylamine) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Assessment of the Acute Effects of 2C-B vs. Psilocybin on Subjective Experience, Mood, and Cognition
Controlled comparison of 2C-B 20mg vs psilocybin in humans showing shorter duration of 2C-B effects (resolving within 6h) with distinct subjective profile and shorter plasma half-life.
-
Acute Pharmacological Effects of 2C-B in Humans: An Observational Study
First systematic documentation of 2C-B acute effects in naturalistic human use, characterizing onset, peak effects, duration, and physiological parameters.
2 published studies referenced in the app, each with a plain-language summary.